Hims & Hers Health, Inc.
Here’s whether Hims & Hers Health, Inc. (HIMS) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Bearish.
Positives: above the 50-day MA (medium-term momentum positive). Concerns: trading below the 200-day MA (long-term downtrend); 50-day MA is falling (-5.78% over 10 days); RSI 79 — overbought, elevated pullback risk; 3-month momentum negative (-8.2%). Currently 59.1% off its 52-week high. Score: -4/7.
HIMS is trading below its 200-day MA ($38.37) — a key warning sign the longer-term trend is under pressure. With an RSI of 78.8, momentum has stretched into overbought territory — short-term pullbacks are common from these levels. The 1-year return of +6.9% compares to +35.1% for SPY (trailed the market by 28.1%). The current 59.1% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.